Prosecution Insights
Last updated: October 02, 2026

Examiner: BATES, KEENAN ALEXANDER

Tech Center 1600 • Art Units: 1631 1699

This examiner grants 46% of resolved cases

Analysis

Keenan Alexander Bates is an examiner in Art Unit 1631 of Tech Center 1600, where he has 77 resolved cases. The allowance rate pct of 45.5 indicates that fewer than half of the applications reaching a final resolution result in a patent grant. This 45.5 percent rate suggests a challenging environment for applicants, requiring careful attention to claim scope and examiner concerns. The median days to allowance is 1296, which reflects a lengthy prosecution timeline for those applications that do eventually succeed. This 1296-day median indicates that practitioners should be prepared for an extended period of examination before reaching a favorable outcome in Tech Center 1600.

The most significant metric for this examiner is the interview lift pct of 79.5. This exceptionally high lift suggests that conducting an interview is a highly effective strategy for overcoming rejections and securing an allowance. By engaging in direct verbal communication, applicants can dramatically improve their chances of success beyond the 45.5 percent baseline. The 77 resolved cases provide a clear indication that interviews are a primary driver of positive outcomes in Art Unit 1631. For practitioners, leveraging this 79.5 percent lift is likely the most efficient way to navigate the 1296-day median prosecution cycle. The data underscores that while the baseline success rate is moderate, proactive engagement can significantly alter the trajectory of an application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

45.5%
Allow Rate
-14.5% vs TC avg
151
Total Applications
+79.5%
Interview Lift
1296
Avg Prosecution Days
Based on 77 resolved cases, 2023–2026

Rejection Statute Breakdown

4.2%
§101 Eligibility
20.2%
§102 Novelty
38.6%
§103 Obviousness
27.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17272203 ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF BEST DISEASE Non-Final OA University of Florida Research Foundation, Incorporated
17600820 Compositions and Methods for Allelic Gene Drive Systems and Lethal Mosaicism Final Rejection The Regents of the University of California
18406302 IMMUNOSELECTED UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCs) AND DOWNSTREAM BIOLOGICS Non-Final OA GLOBUS MEDICAL, INC.
17291070 METHODS OF CELLULAR REPROGRAMMING Non-Final OA BioTissue Holdings Inc.
17280392 IN VITRO GROWTH METHOD FOR HAIR FOLLICULAR EPITHELIAL STEM CELLS Non-Final OA RIKEN
18041447 Methods of Protecting RNA Final Rejection Pfizer Inc.
18892177 METHODS FOR CREATING LINKAGE OF MULTIPLE VIRAL VECTORS FOR INTRACELLULAR DELIVERY Non-Final OA Battelle Memorial Institute
17602730 METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS Non-Final OA The Trustees of the University of Pennsylvania
17601581 COMPOSITIONS AND METHODS FOR IN UTERO GENE EDITING FOR MONOGENIC LUNG DISEASE Final Rejection THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17275084 AUTOMATED GENERATION AND ANALYSIS OF ORGANOIDS Non-Final OA Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
18021675 METHOD OF MAKING RECOMBINANT AAVS Final Rejection Oxford University Innovation Limited
18021691 PROCESS FOR MAKING A RECOMBINANT AAV LIBRARY Final Rejection Oxford University Innovation Limited
18648087 PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF Non-Final OA OSAKA UNIVERSITY
18020734 METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES Non-Final OA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
17771662 HLA CLASS I MOLECULES IN IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS Final Rejection Intellexon GmbH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month